Measurements of TSC2 GAP activity toward Rheb
Related Experiment Video
Updated: Aug 8, 2026
Measuring TCR-pMHC Binding In Situ using a FRET-based Microscopy Assay
Published on: October 30, 2015
Yong Li1, Ken Inoki, Haris Vikis
1Life Sciences Institute, Department of Biological Chemistry, University of Michigan, Ann Arbor, Michigan, USA.
Abstract:
Tuberous sclerosis complex (TSC) is a genetic disease caused by mutation in either the tsc1 or tsc2 tumor suppressor genes. TSC1 and TSC2 protein form a physical and functional complex in vivo. Recent studies have demonstrated that TSC2 displays GTPase activating protein (GAP) activity specifically toward the small G protein Rheb (Ras homolog enriched in brain) and inhibits its ability to stimulate the mammalian target of rapamycin (mTOR) signaling pathway. We have presented three methods to determine the activity of TSC2 as a GAP toward the Rheb GTPase. The first involves the isolation of TSC2 from cells and measurement of its activity toward Rheb substrate in vitro. The second involves the measurement of Rheb-associated guanine nucleotides as measure of TSC2 GAP activity on Rheb in vivo. The last method is to determine the phosphorylation of S6K1 (ribosomal S6 kinase), which is a downstream target of mTOR, as an indirect assay for TSC2 GAP activity in vivo.
Insights
Tuberous sclerosis complex (TSC) is a genetic disorder caused by mutations in TSC1 or TSC2 genes. This study presents three methods to measure the GTPase-activating protein (GAP) activity of TSC2 on the Rheb protein, crucial for mTOR signaling.
Area of Science:
- Genetics
- Molecular Biology
- Biochemistry
Background:
- Tuberous sclerosis complex (TSC) is a genetic disorder resulting from mutations in the TSC1 or TSC2 tumor suppressor genes.
- The TSC1 and TSC2 proteins form a complex that regulates the mammalian target of rapamycin (mTOR) signaling pathway.
- TSC2 possesses GTPase-activating protein (GAP) activity towards the small G protein Rheb, inhibiting mTOR signaling.
Purpose of the Study:
- To present and validate three distinct methods for quantifying the in vitro and in vivo GTPase-activating protein (GAP) activity of TSC2 towards Rheb.
- To establish reliable assays for assessing TSC2's functional role in regulating Rheb-GTP levels and downstream mTOR signaling.
Main Methods:
- In vitro enzymatic assay measuring TSC2's GAP activity on isolated Rheb substrate.
- In vivo assay quantifying Rheb-bound guanine nucleotides to assess TSC2's GAP activity.
- Indirect in vivo assay measuring the phosphorylation of S6K1, a downstream target of mTOR, to infer TSC2 GAP activity.
Main Results:
- The study details three methodologies for assessing TSC2's GAP activity against Rheb.
- These methods allow for both direct and indirect measurement of TSC2's enzymatic function in regulating Rheb.
- The assays provide insights into TSC2's role in controlling the mTOR pathway.
Conclusions:
- The presented methods offer robust approaches to determine TSC2's GTPase-activating protein (GAP) activity.
- These assays are valuable tools for understanding TSC2 function in Tuberous Sclerosis Complex (TSC) pathogenesis.
- Quantifying TSC2 GAP activity is essential for elucidating its regulatory role in the Rheb-mTOR signaling axis.
